OTC · Biotechnology

LadRx Corporation (LADX) Stock

$0.01 -89.72% OTC: LADX Healthcare

LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent that targets and delivers the chemotoxic agent to the tumor environment and release within the tumor.

Valuation

MetricValue
Price$0.01
Market Cap$5446
P/E Ratio0.00
P/B Ratio0.00
P/S Ratio0.00
EPS (TTM)$-3210.89
52-Week High$2.40
52-Week Low$0.01
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE159000.00%
ROA-159000.00%
ROCE255.25%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio0.37

Annual Financials (USD)

Metric20202021202220232024
Revenue$0$0$0$0$0
Operating Profit$-7.0M$-12.0M$-5.0M$-4.0M$-4.0M
Net Profit$-7.0M$-13.0M$-4.0M$0$-1.6B
EPS$-19.34$-35.52$-11.00$0.68$-3210.89
Op Margin—————

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$12.0M$9.0M$2.0M$2.0M$1.0M
Total Liabilities$3.0M$4.0M$2.0M$2.0M$2.0M
Cash$10.0M$7.0M$1.0M$2.0M$1.0M
Borrowings$1.0M$0$0$0$0

Latest News

Why Is HA Sustainable Infrastructure Capital (HASI) Stock Soaring Today StockStory · Aug 11, 2026 Frontera Energy Provides Notice of Second Quarter 2026 Financial Results Conference Call CNW Group · Aug 11, 2026 MaxLinear Introduces Carmel™ High-Speed USB-to-UART Product for Next-Generation AI Data Center Console Access Business Wire · Aug 11, 2026 GAC "Philippines Action" Officially Launches: Coordinated Efforts Across Products, Brand, and Channels to Deepen Footprint in the Philippine Market PR Newswire · Aug 11, 2026 Swiatek races into Toronto semis as Svitolina battles through AFP · Aug 11, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-6.0M$-12.0M$-5.0M$1.0M$-1.3B
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$-6.0M$-3.0M$-5.0M$1.0M$-1.3B
Free Cash Flow$-6.0M$-12.0M$-5.0M$1.0M$-1.3B

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.48
FCF Yield-24060466.40%
Quick Ratio0.37
Interest Coverage0.00
Return 1Y-98.36%
Return 3Y-99.50%
Return 5Y-99.99%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACBMAcro Biomedical Co., Ltd. $0.03 +0.00% -11.30 $1.56M 0.00%
BIOIFBiome Grow Inc. $0.00 — -0.01 $56208 0.00%
DNAGDNAPrint Genomics, Inc. $0.00 — — $12892 0.00%
INSDInstadose Pharma Corp. $0.00 — — $53193 0.00%
MEDVFMedivolve Inc. $0.00 — — $2702 0.00%

About LadRx Corporation

LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent that targets and delivers the chemotoxic agent to the tumor environment and release within the tumor. Its lead candidates comprising LADRs 7, 8, 9, and 10 with novel derivatives of the auristatin and maytansinoid drug targeting tumors; and aldoxorubicin, which is in phase II clinical development for the treatment of pancreatic cancer. In addition, the company develops albumin companion diagnostic (ACDx) to identify patients with cancer that benefits from treatment with the four LADR lead candidates. The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. The company was incorporated in 1985 and is headquartered in Los Angeles, California.

LadRx Corporation is headquartered in US.

LadRx Corporation (LADX) stock trades at $0.01 with a market capitalization of $5446. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.01 and $2.40, and currently trades 99.6% below its 52-week high.

On profitability, LadRx Corporation generates a return on equity (ROE) of 159000.00% — well above the market average, a sign of a high-quality business, return on capital employed of 255.25%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.ladrxcorp.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides